Biotech news
Biotech
The Attorney General for the Court of Justice of the European Union has issued an opinion on the meaning of the term ‘human embryos’ that could "significantly restrict" the scope of the Brüstle decision of 2011. 21 July 2014
Asia
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world. 8 July 2014
Biotech
The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld. 7 July 2014
Americas
Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion. 2 July 2014
Asia
IP legislation in the United Arab Emirates is among the strongest in the region but the courts have had so few issues to handle that the country’s lawyers and judges may not yet be well equipped to deal with biotech cases. 27 June 2014
Americas
Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday. 26 June 2014
Biotech
An increasing trend among scientists to want to put their new ideas into the public domain to be shared for the benefit of all is putting research bodies that rely on partnerships with industry for a substantial proportion of their income at risk, according to Jean Derégnaucourt, executive vice-president for business development at the Institut Pasteur in Paris. 26 June 2014
Biotech
In a discussion about the implications of the US Supreme Court’s decisions on patent-eligible matter in Prometheus and Myriad at the BIO International Convention yesterday, entitled Patent eligibility from the trenches, an audience member expressed concern that uncertainty over patenting rules could drive American innovators overseas. 26 June 2014
Americas
The American public's access to new and effective medicines could be at risk as a result of the US Supreme Court's decisions in the Prometheus and Myriad cases, and the resulting guidance for examiners from the USPTO, according to a report presented to the 2014 BIO International Convention in San Diego today. 25 June 2014
Americas
Teva has reached a settlement in its patent battle with two pharmaceutical companies, ending all litigation over its ProAir HFA (albuterol sulfate) inhalation aerosol. 23 June 2014